Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EONS Poster Display session

CN36 - Fasting in cancer patients during chemotherapy: A monocentric study

Date

15 Sep 2024

Session

EONS Poster Display session

Topics

Supportive Care and Symptom Management;  Patient Education and Advocacy

Tumour Site

Presenters

Wala Ben Kridis

Citation

Annals of Oncology (2024) 35 (suppl_2): S1179-S1184. 10.1016/annonc/annonc1582

Authors

W. Ben Kridis, E. Hadj Taieb, R. Ben Lassoued, A. Khanfir

Author affiliations

  • Medical Oncology Department, University of Sfax - Habib Bourguiba University Hospital, 3029 - Sfax/TN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract CN36

Background

Fasting during the holy month of Ramadan is a religious ritual practiced by the majority of Muslims around the globe. This daytime fasting is short-term or intermittent fasting. Cancer patients under chemotherapy were advised to avoid fasting during chemotherapy. However, we have noticed that some cancer patients are fasting for a spiritual need. The aim of our study was to determine the percentage of cancer patients who are fasting and to assess its tolerance.

Methods

This was a cross-sectional study including cancer patients treated with chemotherapy at the department of medical oncology in Habib Bourguiba university hospital. We questioned cancer patients receiving chemotherapy during April 2024. We determined the percentage of patients who fasted and we studied their tolerance.

Results

60 patients were included. The average age was 57±11.5 years. 60% were women. Colorectal cancer represented 66.7%, stomach cancer 10% and breast cancer 6.7%. It was a localized stage in 44.7% of cases. 53.3% of patients underwent surgery. The systemic treatment at the time of questioning was polychemotherapy in 93.6%. Targeted therapy was associated to chemotherapy in 3.3%. Chemotherapy were linked to a high and moderate incidence of nausea and vomiting in 20% and 40% respectively. The performance status was 1 in 90% and 2 in 10%. 53.3% fasted with an average duration of 18 days. The tolerance of fasting was poor in 43.7%. A postponement of chemotherapy was made in 31.25% compared to 7.14 in patients who did not fast (p=0.004). A decrease in clearance was observed in 12.5% versus 0% (p=0.001). 6.25% progressed after fasting versus 0% (p=0.02).

Conclusions

Our study concluded that fasting during chemotherapy is poorly tolerated, leading to a delay in chemotherapy, which may explain the possibility of disease progression.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Habib Bourguiba Local Committee.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.